search
Back to results

Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment

Primary Purpose

Obesity

Status
Not yet recruiting
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
gastric balloon implantation
botulinum toxin A injection
Sponsored by
Sebahattin Celik MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, gastric balloon, botulinum toxin A, intervention

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: patients with body mass index over 30 patients who have been on a diet and have done sports at least for 6 month and yet could not lose weight. 18-65 years old patients Exclusion Criteria: patients diagnosed with peptic ulcer untraceable patients after injection of botulinum toxin A patients with no history of bariatric surgery or interventions patients who do not retrieve balloon after 6 month or require repetitive implantations.

Sites / Locations

  • Yuzuncu Yil University Faculty of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Only gastric balloon

sequential botulinum toxin A injection and then gastric balloon

Arm Description

After analgesia endoscopy will be performed. After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented. After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.

After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for Botox injection and balloon placement, 200 U of botulinum toxin A will be injected to the antrum and the fundus. After 24 hour or 1 week the second procedure (placement of gastric balloon) will be performed. And Starting from first hour until 1 week, patient's nausea-vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.

Outcomes

Primary Outcome Measures

Number of patients who develop intolerance and undergo balloon removal procedure
Number of patients who develop intolerance and undergo balloon removal procedure
Quality of life measured using SF-36 questionnaire
The acute(1 week) time frame format of Short Form-36 questionnaire will be used to assess health-related quality of life
Nausea-vomiting and retching measured using Rhodes index of nausea-vomiting-retching(RİNVR)
Number of analgesics and muscle relaxants needed
Weight loss

Secondary Outcome Measures

Full Information

First Posted
February 19, 2023
Last Updated
May 23, 2023
Sponsor
Sebahattin Celik MD
search

1. Study Identification

Unique Protocol Identification Number
NCT05872932
Brief Title
Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment
Official Title
Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 2023 (Anticipated)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Sebahattin Celik MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity, which is defined as the accumulation of fat in the body to a degree that impairs health, is defined as a serious public health problem and it is estimated that 13% (approximately 650 million) of the entire world population is obese. There are different methods in the fight against obesity, one of these methods is bariatric interventions. Although bariatric surgery is the most effective of these procedures, the tendency to endoscopic methods is increasing due to the surgical risk. Gastric balloon is the most common endoscopic method. In addition, gastric botox is among the methods used. Health consequences of endoscopic interventions have been widely investigating and while gastric balloon recommended as safe and effective method, the situation for gastric botox is controversial. Although it seems as gastric balloon is an office procedure and safely performed, especially the first week is difficult process for patients. It can also end with abdominal pain, nausea, retching, and eventually a process leading to premature removal of the balloon. In Italian study, Genco et al. reported that out of 2515 patients 11 patients (0.44%) balloon removed due to psychological intolerance. While the reported rate of early gastric balloon removal generally ranges from 0.44% to 16%, De Castro ML. et al. reported the early removal rate as 20%. While the complications related to the gastric balloon are as stated, problems such as nausea, vomiting and cramps after the gastric botox procedure are either not reported or not seen at all. Therefore, we hypothesize that sequential endoscopic procedures (first botox application followed by gastric balloon placement) will reduce these early complications (abdominal pain, nausea, retching) and early removal of the gastric balloon. The only study we have reached regarding combined therapy was done in Turkey. Kanlıöz M et al. reported that combining botox and balloon was found to be more effective in losing weight, but it was stated that it had more side effects. In this study, we think that the side effects may already be related to the balloon. As James A et al. stated in their experimental work, the effectiveness of botox is time dependent. It has been stated that the efficacy is optimal after 6 hours in injections to the pyloric region.The fact that the balloon was inserted in the same session, without waiting for enough time after the botox procedure to be effective, may have reduced the possible protective effect of the botox.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, gastric balloon, botulinum toxin A, intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
126 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Only gastric balloon
Arm Type
Experimental
Arm Description
After analgesia endoscopy will be performed. After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented. After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed. For first day standard medication will be provided. Starting from first hour until 1 week, patient nausea -vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
Arm Title
sequential botulinum toxin A injection and then gastric balloon
Arm Type
Experimental
Arm Description
After analgesia endoscopy will be performed. After diagnostic endoscopy if there is not any gastric pathology that would be contraindication for Botox injection and balloon placement, 200 U of botulinum toxin A will be injected to the antrum and the fundus. After 24 hour or 1 week the second procedure (placement of gastric balloon) will be performed. And Starting from first hour until 1 week, patient's nausea-vomiting and retching scores, re-admission to hospital, quality of life scores will be documented.
Intervention Type
Procedure
Intervention Name(s)
gastric balloon implantation
Intervention Description
After diagnostic endoscopy if there is no any gastric pathology that would be contraindication for balloon placement a gastric balloon will be placed
Intervention Type
Procedure
Intervention Name(s)
botulinum toxin A injection
Other Intervention Name(s)
Gastric balloon implantation 1 week after Botox injection
Intervention Description
After diagnostic endoscopy if there is no any gastric pathology that would be contraindication Botox injection and balloon placement, 200 U of Botox A will be injected to antrum and fundus. And 1 week later gastric balloon will be implanted
Primary Outcome Measure Information:
Title
Number of patients who develop intolerance and undergo balloon removal procedure
Description
Number of patients who develop intolerance and undergo balloon removal procedure
Time Frame
First 6 months after intragastric balloon placement
Title
Quality of life measured using SF-36 questionnaire
Description
The acute(1 week) time frame format of Short Form-36 questionnaire will be used to assess health-related quality of life
Time Frame
The questionnaire will be taken 1 week after the balloon placement
Title
Nausea-vomiting and retching measured using Rhodes index of nausea-vomiting-retching(RİNVR)
Time Frame
The questionnaire will be taken 6 hours after intragastric balloon placement
Title
Number of analgesics and muscle relaxants needed
Time Frame
First week after intragastric balloon placement
Title
Weight loss
Time Frame
6 months after intragastric balloon placement

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients with body mass index over 30 patients who have been on a diet and have done sports at least for 6 month and yet could not lose weight. 18-65 years old patients Exclusion Criteria: patients diagnosed with peptic ulcer untraceable patients after injection of botulinum toxin A patients with no history of bariatric surgery or interventions patients who do not retrieve balloon after 6 month or require repetitive implantations.
Facility Information:
Facility Name
Yuzuncu Yil University Faculty of Medicine
City
Van
ZIP/Postal Code
65080
Country
Turkey

12. IPD Sharing Statement

Learn more about this trial

Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment

We'll reach out to this number within 24 hrs